Previous works have shown the therapeutic potential of different neurotrophic factors for Friedreich’s ataxia, including insulin-like growth factor-1 (IGF-1) (Franco et al., 2012; Sanz-Gallego et al., 2014), Brain-derived Neurotrophic Factor (BDNF) (Katsu-Jiménez et al., 2016) and the range of neuroprotective factors secreted by mesenchymal stem cells (MSCs) (Kemp K. C. et al., 2017; Kemp K. et al., 2017). This evidence concerns the gene IGF1 and Friedreich ataxia.